Psychotic Disorders Research Program
Scott A. Small, MD
Jeffrey Lieberman, MD
Associate Area Leader
The mission of this research area is to advance our understanding of the natural history, etiology, pathophysiology, and treatment of schizophrenia and related psychotic disorders. Faculty research in this area focuses predominantly on pathophysiological mechanisms, biomarker development, and experimental therapeutics. Faculty and staff work collaboratively in determining which studies to initiate, the interpretation of results, the publication strategy, and how resources are obtained and allocated. Included in this process are the support and utilization of the services of a clinical core, which provides infrastructural support and services for subject ascertainment, assessment, study coordination, and data management as well as other core facilities of NYSPI (such as the imaging center, biostatistics, and EEG).
The scope of the area’s research complements and integrates the research of other areas, specifically Neuroscience and Services, Policy and Law, and Mental Health Data Science. As necessary, our faculty collaborates with psychiatry faculty from different areas and expands the scope of its research to carry out translational and basic research studies in the pursuit of specific lines of investigation.
- To pursue research on the etiologies, pathophysiology and treatment of schizophrenia and related psychotic disorders
- To develop new diagnostic methods and biomarkers for diagnosis and treatment development
- To align this research with public mental health needs and scientific opportunities
- To align this research with the education programs and clinical services of the department
- To translate this research into services that can be integrated into the NYS-OMH system of care
Current sponsored research pertains to four main areas of investigation:
- Mechanisms of Disease: Research focusing on pathophysiology underlying pathogenesis, psychopathology and therapeutic targets. A specific focus of this research is on clinical high-risk patients and early psychosis.
- Development of Biomarkers: Research developing procedures using electrophysiologic, MRI and nuclear medicine technologies and applications to validate diagnoses, define diagnostic subgroups, and facilitate the development and use of treatments.
- Experimental Therapeutics: Research to identify biologic targets, novel therapeutic agents, and procedures and translational development through proof of concept.
- Translation of Research: When research findings are thought to be ready for prime-time, effect collaborations with Services, Policy, and Law to develop community-based studies of treatments and interventions, comparative effectiveness studies and demonstration projects for novel treatments or services.